伊沃西单抗联合化疗治疗伴EGFR变异非小细胞肺癌:一项随机临床试验
这项双盲、安慰剂对照、3期随机试验在中国55个中心纳入322例EGFR-TKI治疗后进展的晚期或转移性非小细胞肺癌患者,比较伊沃西单抗联合培美曲塞和卡铂与安慰剂联合化疗的疗效。结果显示,伊沃西单抗组中位无进展生存期为7.1个月,安慰剂组为4.8个月(HR 0.46,95%CI 0.34-0.62,P<.001),客观缓解率分别为50.6%和35.4%。
要点
- 伊沃西单抗联合化疗较安慰剂联合化疗显著延长无进展生存期(7.1个月 vs 4.8个月;HR 0.46)。
- 客观缓解率伊沃西单抗组为50.6%,安慰剂组为35.4%(差异15.6%,P=.006)。
- ≥3级治疗中出现的不良事件发生率伊沃西单抗组为61.5%,安慰剂组为49.1%。
核心结论
- 在EGFR-TKI治疗后进展的非小细胞肺癌患者中,伊沃西单抗联合化疗较安慰剂联合化疗显著改善无进展生存期,安全性可耐受。
研究设计与样本
- 双盲、安慰剂对照、随机3期试验,在中国55个中心开展,2022年1月至2022年11月入组322例合格患者。
- 参与者接受伊沃西单抗(n=161)或安慰剂(n=161)联合培美曲塞和卡铂,每3周一次,共4个周期,随后维持治疗为伊沃西单抗联合培美曲塞或安慰剂联合培美曲塞。
- 主要终点为意向治疗人群中由独立影像审查委员会(IRRC)按实体瘤疗效评价标准1.1版评估的无进展生存期;报告首次计划期中分析结果。
主要发现
- 伊沃西单抗组和安慰剂组的中位年龄分别为59.6岁和59.4岁,女性比例分别为52.2%和50.9%。
- 截至2023年3月10日,中位随访时间为7.89个月;伊沃西单抗组中位无进展生存期为7.1个月(95%CI 5.9-8.7),安慰剂组为4.8个月(95%CI 4.2-5.6),差异2.3个月,HR 0.46(95%CI 0.34-0.62),P<.001。
- 预设亚组分析显示,几乎在所有亚组中伊沃西单抗较安慰剂均有利于无进展生存期,包括第三代EGFR-TKI治疗进展患者(HR 0.48,95%CI 0.35-0.66)和脑转移患者(HR 0.40,95%CI 0.22-0.73)。
- 伊沃西单抗组客观缓解率为50.6%(95%CI 42.6%-58.6%),安慰剂组为35.4%(95%CI 28.0%-43.3%),差异15.6%(95%CI 5.3%-26.0%),P=.006。
- 中位总生存数据尚未成熟;数据截止时,69例患者(21.4%)死亡。
关键数值与推荐
- ≥3级治疗中出现的不良事件:伊沃西单抗组99例(61.5%),安慰剂组79例(49.1%),最常见为化疗相关。
- ≥3级免疫相关不良事件:伊沃西单抗组10例(6.2%),安慰剂组4例(2.5%)。
- ≥3级血管内皮生长因子相关不良事件:伊沃西单抗组5例(3.1%),安慰剂组4例(2.5%)。
临床怎么用
- 对于EGFR-TKI治疗后进展的晚期或转移性非小细胞肺癌患者,伊沃西单抗联合培美曲塞和卡铂可考虑作为治疗选择,但需注意≥3级不良事件发生率高于安慰剂联合化疗。
局限性
- 中位总生存数据尚未成熟。
- 首次计划期中分析结果报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. OBJECTIVE: To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled. INTERVENTIONS: Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed and carboplatin once every 3 weeks for 4 cycles, followed by maintenance therapy of ivonescimab plus pemetrexed or placebo plus pemetrexed. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival in the intention-to-treat population assessed by an independent radiographic review committee (IRRC) per Response Evaluation Criteria in Solid Tumors version 1.1. The results of the first planned interim analysis are reported. RESULTS: Among 322 enrolled patients in the ivonescimab and placebo groups, the median age was 59.6 vs 59.4 years and 52.2% vs 50.9% of patients were female. As of March 10, 2023, median follow-up time was 7.89 months. Median progression-free survival was 7.1 (95% CI, 5.9-8.7) months in the ivonescimab group vs 4.8 (95% CI, 4.2-5.6) months for placebo (difference, 2.3 months; hazard ratio [HR], 0.46 [95% CI, 0.34-0.62]; P < .001). The prespecified subgroup analysis showed progression-free survival benefit favoring patients receiving ivonescimab over placebo across almost all subgroups, including patients whose disease progressed while receiving third-generation EGFR-TKI therapy (HR, 0.48 [95% CI 0.35-0.66]) and those with brain metastases (HR, 0.40 [95% CI, 0.22-0.73]). The objective response rate was 50.6% (95% CI, 42.6%-58.6%) with ivonescimab and 35.4% (95% CI, 28.0%-43.3%) with placebo (difference, 15.6% [95% CI, 5.3%-26.0%]; P = .006). The median overall survival data were not mature; at data cutoff, 69 patients (21.4%) had died. Grade 3 or higher treatment-emergent adverse events occurred in 99 patients (61.5%) in the ivonescimab group vs 79 patients (49.1%) in the placebo group, the most common of which were chemotherapy-related. Grade 3 or higher immune-related adverse events occurred in 10 patients (6.2%) in the ivonescimab group vs 4 (2.5%) in the placebo group. Grade 3 or higher vascular endothelial growth factor-related adverse events occurred in 5 patients (3.1%) in the ivonescimab group vs 4 (2.5%) in the placebo group. CONCLUSIONS: Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in TKI-treated non-small cell lung cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05184712.
引用
- Fang W, Zhao Y, Luo Y, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024. PMID: 38820549. doi:10.1001/jama.2024.10613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。